Table 2. Characteristics of the study cohort per drugs.
| IFX (n = 48) | ETN (n = 175) | ADA (n = 167) | GOL (n = 12) | UST (n = 73) | SEC (n = 37) | |
|---|---|---|---|---|---|---|
| Age, years | 55.1 ± 12.6 | 55.8 ± 12.6 | 55.6 ± 13.1 | 50.2 ± 13.2 | 52.6 ± 13.7 | 54.2 ± 14.6 |
| Male sex, n (%) | 27 (56.2) | 111 (63.4) | 92 (55.1) | 7 (58.3) | 46 (63.0) | 26 (70.3) |
| Follow up, months | 18.4 ± 1.5 | 20 ± 1.3 | 19.1 ± 2.5 | 18 ± 0.5 | 21 ± 1 | 18.4 ± 2 |
| Age first biologic therapy, years | 50.8 ± 13.6 | 50.7 ± 12.9 | 53.3 ± 13.7 | 48.2 ± 13.9 | 50.0 ± 14.5 | 52.5 ± 14.6 |
| Naïve, n (%) | 31 (64.6) | 116 (66.3) | 137 (82.0) | 12 (100) | 63 (86.3) | 35 (94.6) |
| Diagnosis | ||||||
| Plaque psoriasis, n (%) | 23 (47.9) | 82 (46.9) | 92 (55.1) | 0 | 53 (72.6) | 35 (94.6) |
| Psoriatic arthritis, n (%) | 25 (52.1) | 93 (53.1) | 75 (44.9) | 12 (100) | 20 (27.4) | 2 (5.4) |
| Concurrent treatments | 20 (41.7) | 37 (21.1) | 32 (19.2) | 4 (33.3) | 9 (12.3) | 3 (8.1) |
| MTX, n (%) | 15 (31.2) | 15 (8.6) | 17 (9.7) | 3 (25) | 1 (1.4) | 1 (2.7) |
| CyA, n (%) | 15 (31.2) | 29 (16.6) | 21 (12.6) | 1 (8.3) | 7 (9.6) | 3 (8.1) |
| Acitetrin, n (%) | 0 | 3 (1.7) | 1 (0.6) | 0 | 1 (1.4) | 0 |
| CCS, n (%) | 0 | 1 (0.6) | 1 (0.6) | 0 | 0 | 0 |
| NSAIDs, n (%) | 0 | 0 | 0 | 0 | 0 | 0 |
| PUVA, n (%) | 0 | 0 | 1 (0.6) | 0 | 0 | 0 |
| Apremilast, n (%) | 1(2.1) | 0 | 2 (1.2) | 0 | 1 (1.4) | 0 |
| Switched, n (%) | 25 (52.1) | 50 (28.6) | 23 (13.8) | 1 (8.3) | 4 (5.5) | 0 |
| Adverse events | ||||||
| AEs, n (%) | 9 (18.7) | 28 (16) | 30 (17.9) | 4 (33.3) | 11 (15.1) | 0 |
| SAEs, n (%) | 0 | 3 (1.7) | 2 (1.2) | 0 | 0 | 0 |
| AEs onset after treatment initiation, months1 | 8.2 ± 4.3 | 11.2 ± 6.1 | 10.3 ± 5.0 | 7.7 ± 3.5 | 5.4± 4.8 | - |
IFX, infliximab; ETN, etanercept; ADA, adalimumab; GOL, golimumab UST, ustekinumab; SEC, secukinumab; MTX, methotrexate; CyA, cyclosporin A; CCS, corticosteroids; NSAIDs, Nonsteroidal anti-inflammatory drugs; PUVA, Psoralen Ultra-Violet A; AEs, adverse events; SAEs, serious adverse events.
1Excluding immediate administration site reactions and allergic reactions to excipient.